S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:DARE

Daré Bioscience Stock Forecast, Price & News

$1.79
+0.02 (+1.13%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.71
$1.88
50-Day Range
$1.42
$1.79
52-Week Range
$1.10
$3.85
Volume
3.83 million shs
Average Volume
4.16 million shs
Market Capitalization
$137.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.51
30 days | 90 days | 365 days | Advanced Chart
Receive DARE News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.


Daré Bioscience logo

About Daré Bioscience

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Headlines

Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Update
November 18, 2021 |  americanbankingnews.com
Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy
September 24, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DARE
Employees
20
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.42 per share

Profitability

Net Income
$-27.40 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
72,312,000
Market Cap
$137.12 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
11/28/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/29/2022

MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

818th out of 1,391 stocks

Pharmaceutical Preparations Industry

393rd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Daré Bioscience (NASDAQ:DARE) Frequently Asked Questions

Is Daré Bioscience a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Daré Bioscience stock.
View analyst ratings for Daré Bioscience
or view top-rated stocks.

How has Daré Bioscience's stock been impacted by COVID-19 (Coronavirus)?

Daré Bioscience's stock was trading at $1.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DARE stock has increased by 77.2% and is now trading at $1.79.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Daré Bioscience?

Daré Bioscience saw a decline in short interest in November. As of November 15th, there was short interest totaling 1,770,000 shares, a decline of 22.4% from the October 31st total of 2,280,000 shares. Based on an average daily trading volume, of 2,240,000 shares, the short-interest ratio is currently 0.8 days.
View Daré Bioscience's Short Interest
.

When is Daré Bioscience's next earnings date?

Daré Bioscience is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Daré Bioscience
.

How were Daré Bioscience's earnings last quarter?

Daré Bioscience, Inc. (NASDAQ:DARE) issued its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.05. During the same quarter in the prior year, the business earned ($0.24) earnings per share.
View Daré Bioscience's earnings history
.

What price target have analysts set for DARE?

3 brokers have issued 1 year price targets for Daré Bioscience's shares. Their forecasts range from $5.00 to $11.00. On average, they expect Daré Bioscience's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 346.9% from the stock's current price.
View analysts' price targets for Daré Bioscience
or view top-rated stocks among Wall Street analysts.

Who are Daré Bioscience's key executives?

Daré Bioscience's management team includes the following people:
  • Sabrina Martucci Johnson, President, CEO, Secretary & Director
  • Mark Walters, Vice President-Operations
  • Lisa Walters-Hoffert, Chief Financial Officer & Secretary
  • Christine Mauck, Medical Director
  • David Friend, Chief Scientific Officer

What other stocks do shareholders of Daré Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).

What is Daré Bioscience's stock symbol?

Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE."

Who are Daré Bioscience's major shareholders?

Daré Bioscience's stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.80%), Renaissance Technologies LLC (0.46%), Goldman Sachs Group Inc. (0.36%), Jane Street Group LLC (0.24%), BlackRock Inc. (0.17%) and Citadel Advisors LLC (0.09%).
View institutional ownership trends for Daré Bioscience
.

Which major investors are selling Daré Bioscience stock?

DARE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and HighTower Advisors LLC.
View insider buying and selling activity for Daré Bioscience
or view top insider-selling stocks.

Which major investors are buying Daré Bioscience stock?

DARE stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Jane Street Group LLC, Citadel Advisors LLC, Millennium Management LLC, Paradigm Strategies in Wealth Management LLC, and Interwest Venture Management Co..
View insider buying and selling activity for Daré Bioscience
or or view top insider-buying stocks.

How do I buy shares of Daré Bioscience?

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Daré Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $1.79.

How much money does Daré Bioscience make?

Daré Bioscience has a market capitalization of $137.12 million. The biotechnology company earns $-27.40 million in net income (profit) each year or ($0.74) on an earnings per share basis.

How many employees does Daré Bioscience have?

Daré Bioscience employs 20 workers across the globe.

What is Daré Bioscience's official website?

The official website for Daré Bioscience is www.darebioscience.com.

Where are Daré Bioscience's headquarters?

Daré Bioscience is headquartered at 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122.

How can I contact Daré Bioscience?

Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at (858) 926-7655, via email at [email protected], or via fax at 617-494-1544.


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.